Characteristics of patients with del20q
| UPN . | Diagnosis . | Sex . | Age at sampling, y . | Disease duration, mo . | JAK2-V617F, % T . | Complications . | Treatment . |
|---|---|---|---|---|---|---|---|
| p007 | PV | M | 76 | 264 | 92 | sMF, thrombosis | Phlebotomy, IFN, hydroxyurea |
| p020 | PMF | F | 75 | 132 | 0 | Thrombosis | Hydroxyurea |
| p048 | PMF | M | 77 | 168 | 95 | Splenomegaly | NA |
| p103 | PV | F | 82 | 600 | 95 | None | Phlebotomy, hydroxyurea, 32P |
| p187 | PMF | M | 74 | 186 | 59 | Splenomegaly | No treatment |
| Di433 | PV | F | 79 | 22 | 94 | None | Hydroxyurea |
| Na293 | ET | M | 68 | 28 | 16 | Anemia, splenomegaly | No treatment |
| Na391 | ET | F | 41 | 240 | 68 | SVT and other thromboses, sMF, anemia | Hydroxyurea |
| Vi062 | ET | F | 54 | 257 | 10 | Abortion (3 times) | Anagrelide |
| Vi102 | ET | M | 51 | 46 | 23 | MI, melanoma | Anagrelide, hydroxyurea, IFN |
| Vi108 | PMF | F | 59 | 39 | 72 | PAD, insult, splenomegaly | IFN |
| Vi117 | PMF | M | 64 | 43 | 0 | Anemia, splenomegaly | IFN, lenalidomide |
| Vi139 | PV | F | 50 | 52 | 0 | None | IFN, anagrelide, phlebotomy |
| Vi141 | PV | F | 79 | 211 | 11 | Bleeding, TIA | Anagrelide, hydroxyurea, IFN, phlebotomy |
| Vi162 | PMF | M | 67 | 142 | 0 | Anemia, splenomegaly | IFN |
| Vi233 | PMF | M | 80 | 53 | 9 | Lung cancer, DVT, CAD | Hydroxyurea |
| Vi318 | PV | F | 65 | 30 | 12 | PAD | Phlebotomy, hydroxyurea |
| Vi346 | PMF | M | 56 | 72 | 0 | Lung cancer | IFN |
| Vi384 | PV | M | 64 | 197 | 98 | None | Phlebotomy |
| UPN . | Diagnosis . | Sex . | Age at sampling, y . | Disease duration, mo . | JAK2-V617F, % T . | Complications . | Treatment . |
|---|---|---|---|---|---|---|---|
| p007 | PV | M | 76 | 264 | 92 | sMF, thrombosis | Phlebotomy, IFN, hydroxyurea |
| p020 | PMF | F | 75 | 132 | 0 | Thrombosis | Hydroxyurea |
| p048 | PMF | M | 77 | 168 | 95 | Splenomegaly | NA |
| p103 | PV | F | 82 | 600 | 95 | None | Phlebotomy, hydroxyurea, 32P |
| p187 | PMF | M | 74 | 186 | 59 | Splenomegaly | No treatment |
| Di433 | PV | F | 79 | 22 | 94 | None | Hydroxyurea |
| Na293 | ET | M | 68 | 28 | 16 | Anemia, splenomegaly | No treatment |
| Na391 | ET | F | 41 | 240 | 68 | SVT and other thromboses, sMF, anemia | Hydroxyurea |
| Vi062 | ET | F | 54 | 257 | 10 | Abortion (3 times) | Anagrelide |
| Vi102 | ET | M | 51 | 46 | 23 | MI, melanoma | Anagrelide, hydroxyurea, IFN |
| Vi108 | PMF | F | 59 | 39 | 72 | PAD, insult, splenomegaly | IFN |
| Vi117 | PMF | M | 64 | 43 | 0 | Anemia, splenomegaly | IFN, lenalidomide |
| Vi139 | PV | F | 50 | 52 | 0 | None | IFN, anagrelide, phlebotomy |
| Vi141 | PV | F | 79 | 211 | 11 | Bleeding, TIA | Anagrelide, hydroxyurea, IFN, phlebotomy |
| Vi162 | PMF | M | 67 | 142 | 0 | Anemia, splenomegaly | IFN |
| Vi233 | PMF | M | 80 | 53 | 9 | Lung cancer, DVT, CAD | Hydroxyurea |
| Vi318 | PV | F | 65 | 30 | 12 | PAD | Phlebotomy, hydroxyurea |
| Vi346 | PMF | M | 56 | 72 | 0 | Lung cancer | IFN |
| Vi384 | PV | M | 64 | 197 | 98 | None | Phlebotomy |
UPN indicates unique patient number; sMF, secondary myelofibrosis; NA, not available; IFN, interferon; SVT, splanchnic vein thrombosis; TIA, transient ischemic attack; MI, myocardial infarction; PAD, peripheral artery disease; DVT, deep vein thrombosis; and CAD, coronary artery disease.